{'52WeekChange': -0.55495036,
 'SandP52WeekChange': 0.0644362,
 'address1': '7000 Shoreline Court',
 'address2': 'Suite 201',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.1,
 'askSize': 900,
 'averageDailyVolume10Day': 1713887,
 'averageVolume': 598833,
 'averageVolume10days': 1713887,
 'beta': 1.566261,
 'beta3Year': None,
 'bid': 13.95,
 'bidSize': 1200,
 'bookValue': 3.976,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.4104,
 'dayLow': 13.8,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.245,
 'enterpriseToRevenue': None,
 'enterpriseValue': 478395040,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 24.244715,
 'fiftyTwoWeekHigh': 44.3,
 'fiftyTwoWeekLow': 13.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 26838201,
 'forwardEps': -3.59,
 'forwardPE': -3.869081,
 'fromCurrency': None,
 'fullTimeEmployees': 141,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.02898,
 'heldPercentInstitutions': 1.00858,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1529020800,
 'lastSplitFactor': '1:3',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/tricida.com',
 'longBusinessSummary': 'Tricida, Inc., a pharmaceutical company, focuses on '
                        'the development and commercialization of its drug '
                        'candidate, TRC101, a non-absorbed, '
                        'orally-administered polymer designed as a potential '
                        'treatment for metabolic acidosis in patients with '
                        'chronic kidney disease (CKD). The company has '
                        'completed a Phase 3, double-blind, placebo-controlled '
                        'trial of TRC101 in patients with CKD and metabolic '
                        'acidosis. Tricida, Inc. was founded in 2013 and is '
                        'headquartered in South San Francisco, California.',
 'longName': 'Tricida, Inc.',
 'market': 'us_market',
 'marketCap': 693833280,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_254955910',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -213030000,
 'nextFiscalYearEnd': 1640908800,
 'open': 14.35,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '415 429 7800',
 'previousClose': 14.39,
 'priceHint': 2,
 'priceToBook': 3.493461,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.4104,
 'regularMarketDayLow': 13.8,
 'regularMarketOpen': 14.35,
 'regularMarketPreviousClose': 14.39,
 'regularMarketPrice': 14.35,
 'regularMarketVolume': 627707,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 49952000,
 'sharesPercentSharesOut': 0.099,
 'sharesShort': 4945138,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4498334,
 'shortName': 'Tricida, Inc.',
 'shortPercentOfFloat': 0.2959,
 'shortRatio': 9.43,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'TCDA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.311,
 'twoHundredDayAverage': 28.532446,
 'volume': 627707,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.tricida.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}